上海医药：硫酸羟氯喹片获得菲律宾药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the company to market this product in the Philippines, which is expected to positively impact its overseas market expansion and provide valuable experience [1] Group 1 - The Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases exacerbated by sunlight [1] - The approval of the 200mg Hydroxychloroquine Sulfate Tablets signifies the company's qualification to sell this drug in the Philippine market [1] - This development is seen as a step forward for the company in expanding its international presence [1]